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The strength of an excitatory synapse depends on its ability to release glutamate and on the density of 32 
postsynaptic receptors. Genetically-encoded glutamate indicators (GEGIs) allow eavesdropping on 33 
synaptic transmission at the level of cleft glutamate to investigate properties of the release machinery in 34 
detail. Based on the sensor iGluSnFR, we recently developed accelerated versions that allow 35 
investigating synaptic release during 100 Hz trains. Here we describe the detailed procedures for design 36 
and characterization of fast iGluSnFR variants in vitro, transfection of pyramidal cells in organotypic 37 
hippocampal cultures, and imaging of evoked glutamate transients with two-photon laser scanning 38 
microscopy. As the released glutamate spreads from a point source - the fusing vesicle - it is possible to 39 
localize the vesicle fusion site with a precision exceeding the optical resolution of the microscope. By 40 
using a spiral scan path, the temporal resolution can be increased to 1 kHz to capture the peak of fast 41 




One of the fundamental parameters setting synaptic strength is the release probability of the 44 
presynaptic bouton. Release probability is classically assessed in electrophysiological recordings from the 45 
postsynaptic neuron. In neocortex and hippocampus, however, two neurons are frequently connected 46 
by more than one synapse, which makes it very difficult to achieve a situation where responses from a 47 
single synapse can be electrophysiologically isolated. Furthermore, both presynaptic changes (vesicle 48 
depletion, changes in release probability) and changes on the level of postsynaptic receptors (e.g., 49 
phosphorylation, desensitization, saturation, lateral diffusion, and internalization) contribute to the 50 
variability of postsynaptic responses 1,2. These effects become even more difficult to disentangle during 51 
high-frequency stimulation, when all physiological parameters change simultaneously as the synapse 52 
struggles to maintain transmission. Due to these complications, it is an attractive proposition to assess 53 
synaptic physiology with functional imaging methods, as they convincingly isolate responses from a 54 
single synapse even if other synapses on the same neuron are active at the same time. While a large 55 
number of imaging studies used postsynaptic Ca2+ transients as a read-out of synaptic efficacy, it is now 56 
possible to intercept synaptic transmission at the level of cleft glutamate, effectively isolating 57 
presynaptic dynamics from postsynaptic changes.  58 
Overview of optical glutamate sensors 59 
In the last decade, two types of optical glutamate sensors have been developed: chemically-labeled and 60 
genetically-encoded glutamate indicators (GEGIs). Both types of sensors utilize a glutamate-binding 61 
protein which is either labeled with a synthetic fluorophore or fused to a fluorescent protein. Sensors 62 
based on the ligand-binding domain of AMPAR subunit conjugated with a small fluorescent dye molecule 63 
near the glutamate-binding pocket have been used to image bulk extrasynaptic glutamate dynamics in 64 
the brain 3,4. A chemical FRET-based approach, combining a donor and acceptor fluorophore with the 65 
glutamate binding protein iGluR5-S1S2 (Snifit-iGluR5) 5 showed an improved fluorescence change in 66 
cultured cells but has not been applied to brain tissue yet. Sparse and cell-specific labeling without 67 
background fluorescence, a precondition for single-synapse studies, seems to be difficult to achieve with 68 
chemically labeled sensors. 69 
The first fully genetically-encoded glutamate indicator (GEGI) called FLIPE 6 was FRET-based and 70 
contained a glutamate binding protein (GltI from E.coli) located between an N-terminal enhanced cyan 71 
fluorescent protein (ECFP) and a C-terminal yellow fluorescent protein called Venus. Later improved to 72 
reach a maximum CFP/YFP ratio change of 44% and a Kd of 2.5 µM  (Hires et al., 2008), the sensor named 73 
SuperGluSnFR allowed measurements of the time course of synaptic glutamate release and spillover in 74 
hippocampal cultures. However, the signal-to-noise ratio (SNR) of SuperGluSnFR was still low, and ~30 75 
traces had to be averaged to measure glutamate release in response to single action potentials. A 76 
significant improvement was the development of iGluSnFR 9. iGluSnFR is an intensity-based glutamate 77 
sensor constructed from E. coli GltI and circularly permuted (cp) EGFP. Its high fluorescence dynamic 78 
range (ΔF/Fmax of 4.5) and Kd of ~4 µM make it a very suitable tool for investigating cleft glutamate 79 
dynamics. iGluSnFR has been used to measure glutamate in a variety of tissues such as the retina 10, 80 
visual cortex 11 and olfactory bulb 12. We and others developed variants displaying different kinetics, 81 
affinities and emission profiles 13–15. Those new GEGIs with varied biophysical properties enable 82 
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researchers to select the most appropriate sensor depending on the biological question (bulk tissue vs. 83 
single synapse) and imaging system (camera, galvanometric laser scanner, or resonant scanner). 84 
Comparison with other methods to image presynaptic function 85 
To image presynaptic function, fluorescent glutamate sensors are not the only possibility. The change in 86 
vesicular pH during vesicle exocytosis and recycling/reacidification has been successfully exploited to 87 
measure the activity of individual presynaptic terminals. Synapto-pHIuorin, the first genetically-encoded 88 
pH indicator, was based on a pH-sensitive GFP variant fused to the C-terminus of synaptobrevin/VAMP2 89 
(vesicular associated membrane protein-2) to target the sensor to the inner surface of synaptic vesicles 90 
16. Other vesicular targeting strategies used fusion to synaptophysin 17, synaptotagmin 18 and the 91 
vesicular glutamate transporter VGLUT 19. Spectrally red-shifted sensors with a red fluorescent pH-92 
sensitive protein like VGLUT-mOrange2 20 and sypHTomato 21 were developed, and the ratiometric 93 
sensor Ratio-sypHy 22 was instrumental in revealing the arrested development of synapses in dissociated 94 
neuronal culture. In addition, in primary cultures, pHluorins are sufficiently sensitive to detect single 95 
vesicle release events 23–25. It is even possible to localize individual fusion events with a precision 96 
exceeding the resolution limit of the microscope 26. Analysis of release during high-frequency activity, 97 
however, is difficult with pH-based methods: reuptake and reacidification are slow processes, leading to 98 
rapid accumulation of green fluorescence inside active synaptic terminals. Furthermore, pH-based 99 
indicators provide no information about the glutamate content (filling state) of individual vesicles. 100 
Another technique to study presynaptic function is to image the loading and unloading of amphiphilic 101 
styryl dyes (FM dyes), initially developed to study vesicle recycling at the neuromuscular junction (NMJ) 102 
27. The lack of cellular selectivity prevents the use of FM dyes at individual synapses in the densely 103 
packed neuropil. In addition, the relatively long partitioning time of FM dyes in- and out of the 104 
membrane (seconds) renders the relation between staining/destaining events and sub-millisecond 105 
glutamate release rather obscure. 106 
Overview of the Procedure  107 
The Procedure can be divided into two sections (see Fig. 1); sensor development (Steps 1-42) and 108 
functional imaging of synaptic activity in hippocampal slice cultures (Steps 43-62).  109 
Sensor development (Steps 1-42): While iGluSnFR is an excellent general-purpose GEGI, it may be 110 
necessary to further optimize specific properties such as affinity for glutamate (Kd), brightness, or 111 
kinetics for specific experiments. Optimization starts with structure-guided mutations of residues 112 
close to the glutamate binding pocket (Fig. 1a) (Step 1). Newly generated variants are expressed in E. 113 
coli, purified and tested in vitro for glutamate-induced changes in fluorescence (Steps 2-20). If the 114 
dynamic range is deemed sufficient, affinity and kinetics are determined by stopped-flow fluorimetry 115 
(Steps 21-37). The most promising candidates are expressed and characterized in HEK cells (Steps 38-116 
42) and finally, in neurons (Steps 43-62). We found considerable differences in the absolute affinity 117 
and kinetics of sensor molecules in solution compared to the same molecules tethered to the plasma 118 
membrane of cells 13. Relative differences between GEGIs, however, were conserved, validating the 119 
use of in vitro calibrations for sensor optimization. 120 
Imaging synaptic function (Steps 43-62): Single-cell electroporation is the method of choice to 121 
achieve very sparse expression of glutamate sensors in organotypic culture of brain tissue (Fig. 1b) 122 
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(Steps 46-56). The sparse expression makes it easy to follow the axon of a patch-clamped sensor-123 
expressing neuron to a distal projection area, e.g., CA1. While camera-based systems are ideal for 124 
functional imaging in dissociated neuronal culture, two-photon microscopy is typically used to detect 125 
weak functional signals deep in scattering tissue (Steps 57-62). The optimal strategy for functional 126 
imaging depends on the goal of the experiment: to obtain spatial information about the fusion sites 127 
of vesicles on individual presynaptic boutons, we use fast frame scans and slower GEGIs (iGluSnFR) 128 
(Step 62 Option A). To accurately determine the amplitude of individual glutamate transients, a 129 
prerequisite for optical quantal analysis, spiral scans on individual boutons provide increased 130 
temporal resolution and better signal-to-noise ratio (SNR) (Step 62 Option B). While 500 Hz provide 131 
sufficient temporal resolution for iGluSnFR imaging, we increase the spiral scan frequency to 1 kHz 132 
for ultrafast GEGIs. 133 
Limitations of the method 134 
Glutamate diffuses out of the synaptic cleft in less than 1 ms. Even the fastest GEGIs cannot monitor the 135 
true kinetics of free glutamate diffusion as the sensor needs time to rearrange its conformation to 136 
become fluorescent. In addition, scanning microscopy has limited temporal resolution. For capturing 137 
sub-millisecond fluorescence changes, it would be necessary to park the excitation beam on the synaptic 138 
cleft. This is not a technical problem, but in practice, point-scan experiments are extremely sensitive to 139 
small lateral movements of the active bouton in the tissue. At the moment, galvanometric scanning can 140 
still adequately sample the fastest GEGIs. 141 
The number of trials that can be obtained from a single bouton is limited by the unavoidable bleaching of 142 
the indicator molecules and eventual destruction of the release machinery by toxic photoproducts (e.g., 143 
oxygen radicals). Therefore, the laser exposition per single AP should be reduced to a minimum. To 144 
measure GEGI transients in response to individual APs, we image in spiral mode for ~ 80 ms. We 145 
routinely acquire ~100 trials from single boutons without any decay in amplitude or release probability 146 
(see Experimental design and Supplemental Fig. 1c). By using lower laser power, this number can be 147 
extended to 200 trials at the cost of a slightly lower SNR. Longer intervals between trials allow 148 
replenishing indicator molecules by lateral diffusion, but this strategy is limited by the need for stable 149 
whole-cell access during the entire experiment for reliable action potential generation.  150 
Experimental design 151 
Development and characterization of fast glutamate probes: Site-directed mutagenesis and protein 152 
expression/purification are done following standard procedures and should lead to high yields of the 153 
GEGIs with a purity > 90% in a single-step purification process (determined by SDS-PAGE). One of the 154 
most important parameters is the fluorescence dynamic range (F+glu - F-glu / F-glu) which is a measure of the 155 
fluorescence change upon glutamate binding. If the dynamic range of the new GEGI variant is < 2, the 156 
probe’s response to glutamate is not high enough to be suitable for cellular experiments. 157 
The affinity of the GEGI, expressed as Kd, has to be appropriate for the expected glutamate concentration 158 
in the cellular or tissue environment. If the goal of the experiment is to distinguish synaptic failures (no 159 
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glutamate release, no GEGI signal) from successes (stimulation-induced glutamate release), a very high 160 
affinity is desirable. If a linear response is important, e.g., to estimate the number of vesicles released 161 
simultaneously, a slightly lower affinity might be advantageous. For a GEGI to be a useful probe for in 162 
vivo imaging, it also needs to be specific for glutamate. Therefore, binding to other ligands has to be 163 
assessed (Fig. 2a). As iGluSnFR is based on the glutamate/aspartate ABC transporter protein (Gltl), it is 164 
expected that the sensor retains a significant affinity for aspartate. However, it should be unresponsive 165 
to serine or glutamine. Most of the GEGIs indeed show a fluorescence response to aspartate binding, 166 
sometimes even with higher fluorescence dynamic range than for glutamate. However, the affinity is 167 
often lower, and fortunately, aspartate does not act as a neurotransmitter. Nevertheless, aspartate 168 
sensitivity needs to be considered when monitoring glutamate in non-neuronal tissues or cellular 169 
compartments.  170 
To observe fast events like neurotransmission in synapses, the kinetics of the formation and decay of the 171 
fluorescence state are critical. Thus, the association and dissociation of the purified GEGIs are 172 
determined in vitro by stopped-flow fluorimetry (Fig. 2b). While performing association measurements, 173 
it is essential to record baselines for the buffer to obtain the zero level of the PMT and for the glutamate-174 
free GEGI to obtain the starting point of the fluorescence increase. This recording is essential to detect 175 
rapid phases (>1000 s-1) that are faster than the resolution of the stopped-flow device (about 1 ms 176 
mixing time) and thus appear as jumps. Recording the dissociation of glutamate from the GEGIs is 177 
especially challenging, as the glutamate needs to be removed from the sensor, which is difficult due to 178 
lack of chemical traps. We circumvent this obstacle by mixing the glutamate-bound GEGI with the high 179 
affinity GluBP 600n (Kd about 600 nM) 6. However, for low affinity variants, these measurements are 180 
limited by the concentration of GluBP 600n available and by the very small decrease in fluorescence 181 
amplitude. Low-affinity GEGIs (Kd > 1 mM) have to be saturated with glutamate concentrations in the 182 
mM range, however, GluBP 600n is at best concentrated to be ~ 1 mM in the optical cell. As only a small 183 
fraction of the GEGI is dispossessed of its glutamate, only a very small decrease in fluorescence occurs 184 
and, thus a small signal is observed.  185 
For in vivo use of the GEGIs, the sensors need to be attached to the outer membrane of a cell. Thus, the 186 
sensors are cloned in mammalian expression vectors, which add a mouse Ig κ-chain for secretion and a 187 
PDGFR transmembrane helix for membrane attachment. In order to confirm correct localization, the 188 
sensor is expressed in cell lines (HEK293T cells) and titrated with glutamate to determine the cellular Kd. 189 
We found that the attachment to the outer membrane of the cell increases the variants’ affinity for 190 
glutamate by a factor of up to 20-fold. Relative differences between the variants, however, are 191 
conserved 13. This affinity increase needs to be considered when choosing a suitable sensor for in vivo 192 
applications. 193 
Imaging synaptic glutamate release with two-photon microscopy: For expression in neurons, we clone 194 
the GEGIs behind the human synapsin 1 promoter and electroporate single neurons in organotypic slice 195 
cultures of rat hippocampus. GEGIs are relatively dim in the absence of glutamate, making it difficult to 196 
focus on small structures such as axonal boutons. We routinely use co-expression of a bright red 197 
fluorescent protein (tdimer2 or tdTomato) to label the cytoplasm and follow the axon through the tissue; 198 
the newly developed CyRFP1 28 is also an excellent choice for this purpose. The red fluorescence also 199 
7 
 
provides additional information about the volume of individual boutons. Electroporated CA3 neurons are 200 
clearly visible under a stereomicroscope (5x objective, DsRed filter set) 2-4 days after electroporation 201 
(Fig. 3a-c). Two-photon excitation at 980 nm reveals axons and boutons of the expressing neurons in CA1 202 
stratum radiatum, far away from the somata in CA3 (Fig. 3c). Targeted patch-clamp recording from a 203 
transfected neuron allows triggering single action potentials (APs) by brief depolarizing current injections 204 
(Fig. 3e). Simultaneous imaging of a single bouton (spiral scan path at high zoom (Fig. 5a-c)) reveals green 205 
fluorescence transients time-locked to the action potentials, indicating glutamate release from the 206 
stimulated bouton. In spite of reliable action potential generation, synapses frequently failed to release 207 
glutamate (Fig. 3e, gray traces), indicating a stochastic vesicle fusion process. 208 
Fusion site localization: While spiral scans are optimal to determine the peak amplitude of the 209 
glutamate signal, we use fast frame scans (16 x 16 pixels, frame rate 62.5 Hz) to localize the likely 210 
location of the fusing vesicle in individual trials. The spatial peak of the averaged signal does not 211 
necessarily occur in the center of the bouton, but often close to the edge (Fig. 4b), reflecting the random 212 
orientation of the synaptic cleft on the surface of the bouton. To localize individual fusion events in noisy 213 
images, we fit a two-dimensional Gaussian kernel (Fig. 4c) to the first frame after stimulation. Plotting 214 
the center positions of Gaussian fits (Fig. 4c) relative to the morphological outline of the bouton (red 215 
channel) revealed a small region of release, the active zone (Fig. 4d). Increasing the extracellular Ca2+ 216 
concentration from 1 mM to 4 mM did increase the amplitude of single-trial responses, but not the size 217 
of the apparent active zone (Fig. 4e). The higher cleft glutamate concentrations caused by single action 218 
potentials in 4 mM Ca2+ suggest the simultaneous release of multiple vesicles or a switch from partial to 219 
full release. No clustering was found when we fitted green fluorescence before stimulation or in trials 220 
classified as failures (Fig. 4f and g). 221 
Spiral scans and amplitude extraction: As we do not know a priori where on the bouton the highly 222 
localized and short-lived GEGI signals will appear (Fig. 5a), we need to sample the entire surface of the 223 
bouton as fast as possible. Traditional raster scanning (Fig. 5b) requires extreme acceleration of the 224 
scanning mirror at the end of every scan line, limiting the maximum frame rate to ~120 Hz. By scanning a 225 
spiral pattern, we are able to sample the same area at frequencies up to 1 kHz. The point spread function 226 
(PSF) of our two-photon microscope is 0.5 µm in the imaging plane and 1.7 µm along the optical axis 227 
(FWHM, measured with 170 nm fluorescent beads). As the PSF is elongates in the axial direction, we 228 
sample the upper and lower surface of the bouton simultaneously. Our goal is to extract the amplitude 229 
of fluorescent transients from spiral scans independent of the exact position of the fusion site on the 230 
bouton. To do so, the unfolded spiral scans are plotted as straight lines underneath each other, resulting 231 
in a space-time plot (Fig. 5c). Typically, the spiral scan intersects the diffusing cloud of glutamate two or 232 
three times per scan, resulting in multiple ‘hot spots’ that all contained information about the same 233 
release event. To extract amplitude information, columns (corresponding to positions on the bouton) are 234 
sorted according to the change in fluorescence (Fig. 5d). The columns with the largest signal (ΔF > 235 
ΔFmax/2) are averaged (region of interest, ROI). In trials where no fluorescence change is detected 236 
(failures), the same columns as in the last ‘success’ trial are analyzed. As opposed to a static region-of-237 
interest (ROI), this analysis procedure is robust against minute drift of the tissue between trials and does 238 
not require a priori knowledge of the fusion location. We extract the amplitude from the resulting 239 
fluorescence trace by fitting a single exponential function to the decay of the fluorescence transient. To 240 
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estimate the noise level (photon shot noise) in every experiment, we perform the same fitting procedure 241 
to a section of the baseline (before stimulation). As expected, the baseline amplitudes are close to zero 242 
(Fig. 5f, gray dots and columns). Typically, the histogram of all responses (green) also show one cluster 243 
around zero (failures of release), the remaining responses (successes) form an asymmetric, broad peak 244 
between 40 and 160% ΔF/F0. A close inspection of the spatial distribution of the signal (Fig. 5e, average 245 
of 10 successes) shows a rapid decay of the peak, but no lateral spread as might be expected from a 246 
diffusion process. It is important to note that the diffusion of free glutamate out of the synaptic cleft 247 
happens in less than 1 ms and cannot be resolved by iGluSnFR or another GEGI. Instead, what we 248 
observe is the relatively slow unbinding of glutamate from quasi-stationary iGluSnFR molecules, 249 
explaining the lack of lateral spread of the signal. 250 
 251 
Materials 252 
Reagents  253 
• Plasmids 254 
o pCMV iGluSnFR (Addgene plasmid #41732) 9, iGluSnFR in mammalian expression vector, 255 
can be used for expression in HEK293T cells and as starting point for SDM to induce new 256 
mutations 257 
o pET41a(+) (Novagen, Merck cat. no. 70556-3), bacterial expression vector used to 258 
express GEGI variants in E. coli 259 
o pET30b (Merck cat. no. 69909), bacterial expression vector used to express GEGI variants 260 
in E. coli 261 
o pCI syn iGluSnFR (Addgene plasmid #106123), mammalian expression vector to express 262 
iGluSnFR in neurons (hippocampal slices) 263 
o pDisplay FLIPE-600n (Addgene plasmid # 13545) 6, vector encoding for GluBP 600n for 264 
expression of glutamate-binding protein GluBP 600n in E. coli. Purified GluBP is used for 265 
kinetic analysis in vitro. 266 
o pCI syn iGluf (Addgene plasmid #106121)13, mammalian expression vector for expression 267 
of iGluf in neurons 268 
o pCI syn iGluu (Addgene plasmid #106122)13, mammalian expression vector for expression 269 
of iGluu in neurons 270 
o pCI syn tdimer2, a gift of Roger Y. Tsien 29, mammalian expression vector for expression 271 
of dimeric red fluorescent protein in neurons 272 
• Cloning and molecular biology 273 
o Restriction enzymes: BglII, NotI (NEB cat. no. R0144 and R0189) 274 
o T4 DNA ligase (NEB cat. no. M0202)  275 
o QuikChange XL Site-Directed Mutagenesis Kit (Agilent Technologies cat. no. 200516) 276 
o NucleoSpin® Plasmid kit (Machery and Nagel cat. no. 740588) 277 
o HiSpeed Plasmid Midi Kit (Qiagen cat. no. 12643) 278 
o LB Broth (Powder) - Lennox (Fisher BioReagents cat no. BP1427)  279 
o LB Agar, Lennox (Granulated) (Fisher BioReagents cat no. BP9745) 280 
o Kanamycin sulfate (Fisher BioReagents cat no. BP906)  281 
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CAUTION: toxic. Wear protective gloves, clothing, and eye protection. Wash hands 282 
thoroughly after handling.  283 
o PureLink HiPure Plasmid Maxiprep (Life Technologies cat. no. K210006) 284 
• General reagents 285 
o HEPES (Fine White Crystals/Molecular Biology) (Fisher Scientific cat. no. BP310-1) 286 
o Sodium chloride, BioXtra, ≥99.5% (AT) (Merck cat. no. S7653) 287 
o 1 M MgCl2 solution (Invitrogen AM9530G) 288 
o Sodium hydroxide (Merck cat no. S8045) 289 
CAUTION: Danger. Corrosive to metals and causes severe skin burns and eye damage. 290 
Wear protective gloves, clothing, and eye protection. Wash hands thoroughly after 291 
handling. 292 
o D(+)-Glucose (Merck cat no. D9434) 293 
o Potassium chloride, BioXtra, ≥99.0% (Merck cat no. P9333) 294 
o NaH2PO4 (Merck cat no. S0751) 295 
• Protein expression and purification 296 
o Pierce™ Protease Inhibitor Tablets, EDTA-free (Thermo Fisher Scientific cat. no. A32965) 297 
CAUTION: Danger, causes severe skin burn and eye damage. Wear protective gloves, 298 
clothing and eye protection. Wash hands thoroughly after handling.  299 
CRITICAL: EDTA-free inhibitor is critical to ensure binding of the His tagged protein to the 300 
HisTrap High Performance column 301 
o HisTrap™ High Performance (GE Healthcare cat. no. 17524801) 302 
o SnakeSkin™ Dialysis Tubing, 3.5K MWCO, 22 mm (Thermo Fisher Scientific cat. no. 303 
68035) 304 
• Glutamate, aspartate, and serine titration 305 
o L-Glutamic acid (Merck cat. no. G1251) 306 
o L-Aspartic acid (Merck cat. no. A8949) 307 
o L-Serine (Merck cat. no. S4500) 308 
• Testing in cell lines 309 
o HEK293T cells (Merck cat. no. 85120602) 310 
CAUTION: The cell lines used in your research should be regularly checked to ensure 311 
they are authentic and are not infected with mycoplasma. 312 
o Sensorplate, 24 well, PS, F-bottom, glass bottom, black, lid, sterile, single packed 313 
(Greiner bio one cat. no. 662892) 314 
o DMEM, high glucose, GlutaMAX™ Supplement, pyruvate (Gibco, Thermo Fisher Scientific 315 
cat. no. 31966047) 316 
o MEM Non-Essential Amino Acids Solution (100X) (Gibco, Thermo Fisher Scientific cat. no. 317 
11140035) 318 
o Fetal Bovine Serum (FBS), qualified, heat inactivated, E.U.-approved, South America 319 
Origin (Gibco, Thermo Fisher Scientific cat. no. 10500056) 320 




CAUTION: Causes skin irritation, eye irritation, may cause an allergic skin reaction and 323 
respiratory irritation. Wear protective gloves, clothing, and eye protection. Wash hands 324 
thoroughly after handling.  325 
o Lipofectamine™ 2000 Transfection Reagent (Thermo Fisher Scientific cat. no. 11668027) 326 
• Slice culture and recording 327 
o Slice cultures from rodent hippocampus 30 328 
CAUTION: Any experiments involving live rats must conform to relevant Institutional and 329 
National regulations. In our case, organ explant procedures were approved by the 330 
veterinary of the University Medical Center Hamburg-Eppendorf, Germany 331 
o MEM (Sigma-Aldrich cat. no. M7278) 332 
o Heat-inactivated horse serum (Gibco cat. no. 16050-122) 333 
o L-glutamine (200 mM; Gibco cat. no. 25030-024) 334 
o L-ascorbic acid (Sigma-Aldrich, cat. no. A5960) 335 
o Insulin (1 mg/mL; Sigma-Aldrich cat. no. I1882) 336 
o HEPES (Sigma-Aldrich cat. no. H4034) 337 
o K-gluconate (Sigma-Aldrich, cat. no. G4500) 338 
o EGTA (Sigma-Aldrich, cat. no. E0396) 339 
o Na2-ATP (Sigma-Aldrich, cat. no. A3377) 340 
o Na-GTP (Sigma-Aldrich, cat. no. G8877) 341 
o Na2-phosphocreatine (Sigma-Aldrich, cat. no. P7936) 342 
o NaHCO3 (Sigma-Aldrich, cat. no. S5761) 343 
o NaH2PO4 (Sigma-Aldrich, cat. no. S5011) 344 
o Potassium chloride (Sigma-Aldrich, cat. no. S5886) 345 
o 1 M KCl (Fluka cat. no. 60121) 346 
o 1 M MgSO4 (Fluka cat. no. 63126) 347 
o 1 M MgCl2 (Fluka, cat. no. 63020) 348 
o 1 M CaCl2 (Fluka cat. no. 21114)  349 
o D-glucose (Fluka cat. no. 49152) 350 
o Cl3Fe (Fluka cat. no. 10695862) 351 
Reagent Setup 352 
Resuspension buffer for expression: 50 mM HEPES-Na+, 200 mM NaCl, pH 7.5, filtered (0.2 µm 353 
pore size) and stored at 4°C for 2 weeks 354 
Elution buffer for expression: 50 mM HEPES-Na+, 200 mM NaCl, 500 mM imidazole, pH 7.5, 355 
filtered (0.2 µm pore size) and stored at 4°C for 2 weeks 356 
Storage buffer for expression: 50 mM HEPES-Na+, 100 mM NaCl, pH 7.5, stored at 4°C for 2 357 
weeks 358 
Assay buffer for biophysical characterization: 50 mM HEPES-Na+, 100 mM NaCl, 2 mM MgCl2, 359 
pH 7.5, stored at 4°C for 2 weeks 360 
Association buffers for biophysical characterization:  361 
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• 1 µM GEGI in assay buffer, stored at 4°C for one day.  362 
• 0.1x Kd to 10x Kd glutamate in assay buffer, stored at 4°C for one day 363 
CRITICAL: In order to measure the full range of response in dependence of the glutamate 364 
concentration, the glutamate concentration mixed with the GEGI has to be distributed around 365 
the Kd 366 
Dissociation buffers for biophysical characterization:  367 
• 2 mM GluBP 600n in assay buffer, stored at 4°C for one day.  368 
• 1 µM GEGI in assay buffer, stored at 4°C for one day.  369 
• 1 µM GEGI in assay buffer with saturating glutamate (10x Kd), stored at 4°C for one day 370 
Complete DMEM: DMEM, 1x NEAA, 10% (v/v) FBS, 100 U/ml penicillin-streptomycin, stored at 371 
4°C for 2 month. 372 
HEK293T cell imaging buffer: 20 mM HEPES-Na+, 145 mM NaCl, 10 mM glucose, 5 mM KCl, 1 mM 373 
MgCl2, 1 mM NaH2PO4, pH 7.4 stored at 4°C for up to 6 month. 374 
Slice culture medium: 394 ml MEM, 20% (v/v) Heat-inactivated horse serum, 1 mM  L-glutamine, 375 
0.01 mg/ml Insulin, 14.5 mM NaCl, 2 mM MgSO4, 1.44 mM CaCl2, 0.00125% Ascorbic acid, 13 mM  376 
D-glucose. Medium has to be sterile filtered (0.2 µm pore size) and stored at 4°C for up to 4 377 
weeks. 378 
Slice culture transduction solution: 10 mM HEPES, 145 mM NaCl, 25 mM D-glucose, 2.5 mM KCl, 379 
1 mM MgCl2, 2 mM CaCl2.  Measure the pH using a pH-meter and adjust to pH 7.4 by adding 380 
NaOH or HCl. Measure the osmolality with a micro-osmometer and ensure that the osmolality is 381 
between 310-320 mOsm/kg. If the osmolality is out of range, a mistake was made during 382 
solution preparation. Solution has to be sterile filtered (0.2 µm pore size), stored at 4°C for up to 383 
6 months and pre-warmed to 37°C before use. 384 
Recording solution, artificial cerebrospinal fluid (ACSF): 25 mM NaHCO3, 1.25 mM NaH2PO4, 127 385 
mM NaCl, 25 mM D-glucose, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, pH adjusted to 7.4, ACSF has 386 
to be saturated with 95% O2 and 5% CO2. Osmolality should be between 310-320 mOsm/kg. 387 
Store for max. 1 week at 4°C. Bubble with Carbogen (95% O2, 5% CO2) during warm-up to 388 
prevent Ca2+ precipitation. Maintain perfusion reservoir at 34°C to prevent bubble formation in 389 
recording chamber.  390 
K-gluconate-based intracellular solution: 10 mM HEPES, 135 mM K-gluconate, 0.2 mM EGTA, 4 391 
mM MgCl2,4 mM Na2-ATP, 0.4 mM Na-GTP, 10 mM Na2-phosphocreatine, 3 mM L-ascorbic acid, 392 
pH adjusted to 7.2 with KOH. Osmolality should be between 290-300 mOsm/kg. Solution has to 393 
be sterile filtered (0.2 µm pore size), stored at -20°C. Aliquot in Eppendorf tubes can be stored at 394 
-80°C for max. 6 months. Store on ice during the experiment to slow down ATP hydrolysis. 395 
Equipment  396 
• Equipment for protein expression/purification 397 
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o Sonicator for lysing E. coli (Sonics & Materials Inc., VibraCell) 398 
o ÄKTA Purifier or Explorer (GE healthcare) 399 
• Equipment for biophysical characterization 400 
o Fluorescence spectrometer with magnetic stirring function (Fluorolog3, Horiba Scientific) 401 
o Hellma® fluorescence cuvettes, ultra Micro (Merck, cat. no. Z802336-1EA) 402 
o Hellma fluorescence cuvette QS 3500 µL (Merck, cat. no. Z600172-1EA) 403 
o ALADDIN syringe pump (World Precision Instruments, cat. no. AL-1000) 404 
o SGE syringe 250 μL, barrel inner diameter 2.30 mm (Trajan Scientific and Medical, cat. 405 
no. P/N 006230) 406 
o ‘KinetAsyst’ Dual-mixing Stopped-Flow System (TgK Scientific, cat. no. SF-61DX2) 407 
equipped with two circulating water baths for temperature control and a long-pass filter 408 
>530 nm. The equipment should be set up in a dark lab with red light illumination and 409 
temperature control (20°C) 410 
• Equipment for imaging in cell lines 411 
o Inverted spinning-disk confocal fluorescence microscope (3i Marianas) 412 
• Electrophysiology equipment 413 
o pE-4000 LED light source (CoolLED) for epifluorescence 414 
o infrared Dodt contrast (Luigs & Neumann) 415 
o Patch-clamp amplifier (Axon Instruments, model no. MultiClamp 700B) 416 
o Microelectrode manipulator (Sutter Instrument, MP-285).  417 
o Micropipettes for whole-cell recording (Borosilicate glass with filament, 1.5 mm O.D.) 418 
• Electroporation equipment 419 
o Upright microscope with a motorized stage, CCD camera and IR-DIC (infrared differential 420 
interference contrast) or Dodt contrast 421 
o 20x water immersion objective (Zeiss Achroplan) 422 
o 4x zoom lens system (0.5 – 2.0x magnification range) 423 
o Vibration isolation table (Table Stable LTD, TS-150)   424 
o Axoporator 800A with HL-U pipette holder (Molecular Devices) 425 
o Plastic syringe body (1 ml) as disposable mouthpiece, connected through a Luer 1-way 426 
stopcock and thin silicone tubing to the electrode holder 427 
o Headphones and speakers 428 
o Microscope chamber made of a glass microscope slide (70 x 100 x 1 mm) onto which a 429 
Teflon ring (inner diameter:  ~ 35 mm, height: 2 mm) is fixed with silicone aquarium 430 
sealant 431 
o Motorized micromanipulators (Luigs & Neumann) 432 
o Silver wire (diameter: ~ 0.25 mm) 433 
o Forceps (Fine Science Tools, cat. no. 11002-16) 434 
o Hot bead sterilizer (Fine Science Tools, cat. no. 18000-45) 435 
o Incubator (37°C; 5% CO2) with rapid humidity recovery and copper chamber (Heracell 436 
150i/160i, Thermo Scientific) 437 
o Micropipette puller (PC-10, Narishige) 438 
o Thin-walled borosilicate glass capillaries (WPI, cat. no.  TW150F-3) 439 
13 
 
o Tissue culture dishes (60 mm, sterile; Sarstedt, cat. no. 83.1801) 440 
o Ultrafree centrifugal filter units (Millipore, cat. no.UFC30GV0S) 441 
o Micro-osmometer (Fiske Model 210) 442 
CRITICAL: The electroporation microscope should be situated close to the tissue culture 443 
hood (in the same room) to prevent contamination. We built a laminar flow cabinet with 444 
HEPA filter unit around the electroporation setup. The microscope has to be 445 
mechanically isolated from the vibrations generated by the fan in the filter box; we use 446 
an active anti-vibration table.  447 
• Software 448 
o ImageJ2 (https://imagej.net/ImageJ2) 449 
o GraphPad Prism 7 (https://www.graphpad.com/) 450 
o ScanImage 3.8 31 (https://vidriotechnologies.com/) 451 
o Ephus 32  (https://www.janelia.org/open-science/ephus) 452 
Equipment Setup 453 
o Equipment for functional imaging in tissue: We built a two-photon microscope based on 454 
an Olympus BX51WI microscope with pE-4000 LED light source (CoolLED) for 455 
epifluorescence and infrared Dodt contrast (Luigs & Neumann). A Ti:Sapphire laser 456 
system with dispersion compensation (MaiTai DeepSee, Spectra Physics) was coupled in 457 
through an electro-optical modulator (EOM, Conoptics), a 3x telescope (Thorlabs), 5 mm 458 
scan mirrors (Cambridge), a compound scan lens (f = 50 mm 33), a dual camera port with 459 
IR mirror (Olympus) and a water immersion objective (LUMPLFLN 60XW, 60x, NA 1.0, 460 
Olympus). Red and green fluorescence was detected through the objective and the oil 461 
immersion condenser (NA 1.4, Olympus) using 2 pairs of photomultiplier tubes (H7422P-462 
40SEL, Hamamatsu). 560 DXCR dichroic mirrors and 525/50 and 607/70 emission filters 463 
(Chroma Technology) were used to separate green and red fluorescence. Excitation light 464 
was blocked by short-pass filters (ET700SP-2P, Chroma). During epifluorescence 465 
illumination, sub-stage PMTs were protected by a NS45B shutter (Uniblitz). For electrical 466 
stimulation of individual neurons, we mounted the head-stage of a MultiClamp 700B 467 
amplifier (Molecular Devices) on a MP-285 micromanipulator (Sutter Instruments) on a 468 
motorized stage (40-40, Danaher Motion) that also moved the perfusion chamber 469 
(quartz glass bottom). Temperature was controlled by Peltier-heating of the oil-470 
immersion condenser and in-line heating of the perfusion solution (Warner Instruments). 471 
The setup was controlled by Matlab software (ScanImage 31 and Ephus 32) via data 472 
acquisition boards (National Instruments). At the start of a trial, electrophysiology and 473 
image acquisition were synchronized by a hardware trigger (TTL pulse). During a trial (2 s, 474 
typically), laser power was regulated via EOM and restricted to the periods of expected 475 
glutamate release (20 - 80 ms window, depending on GEGI kinetics) to minimize 476 
bleaching.  477 
CRITICAL: To minimize bleaching by excessive excitation, the microscope has to be 478 
designed to detect emitted photons very efficiently. Using only the objective for 479 
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fluorescence detection is not sufficient to achieve single-vesicle sensitivity. Condenser 480 
detection (oil-immersion, 1.4 NA, large field of view) is essential for the success of single 481 
synapse experiments with many trials. Replace aging PMTs with excessive dark counts.  482 
CRITICAL: The oil-immersion condenser has to be permanently heated (day and night) if 483 
a recording temperature above room temperature is desired. This can be achieved with 484 
flexible heating pads or Peltier elements. As the thermal mass of the condenser is very 485 
large, constant-current heating is sufficient, provided that the temperature of the 486 
perfusion solution is additionally regulated by a feedback control circuit (in-line heater, 487 
Warner Instruments). A climate chamber would be an attractive solution but is not 488 
compatible with direct-mounted PMTs.  489 
CRITICAL: If a galvanometric scanning system is used, the microscope software has to 490 
support arbitrary line scans or spiral scans34. The code for arbitrary line scans that we 491 
developed for our original study is now incorporated in the ScanImage software (Version 492 
2016 and later). ScanImage is developed and supported by Vidrio Technologies, LLC as an 493 
open-source research resource. A resonant scanning system may be sufficiently fast in 494 
frame mode if extreme zoom-in (few scan lines) can be realized. 495 
Procedure 496 
Generation of GEGIs Timing 1 week (5 h hands-on time) 497 
CRITICAL: We have made a number of GEGI-encoding plasmids available via Addgene (see Reagents). 498 
Follow Steps 1-42 in order to design GEGIs with tailored biophysical parameters. 499 
1. Analyze protein 3D structures of the 99% homolog of GltI of Shigella flexneri (PDB 2VHA) and 500 
literature 35,36 to assign critical residues involved in glutamate binding. Substitute essential 501 
residues with amino acids with similar physical properties. Avoid radical changes in amino acid 502 
size or charge as this will frequently result in misfolded or otherwise non-functional proteins.  503 
2. Subclone the iGluSnFR gene from a mammalian expression vector into a bacterial expression 504 
vector (pET41a) using restriction digestion of BglII and NotI and ligation (T4 DNA ligase) following 505 
the manufacturer's protocol. 506 
CAUTION: Subcloning requires DNA to be analyzed by agarose gels. This requires the use of DNA 507 
intercalating fluorescent dyes (e.g. ethidium bromide or Sybr green) which highly toxic as 508 
mutagens and should be handled with care. DNA imaging systems are based on UV lamps so 509 
appropriate personal protective equipment should be used. 510 
3. Insert point mutations using the QuikChange XL site-directed mutagenesis kit following the 511 
manufacturer's instructions and confirm new variants by DNA sequencing.  512 
4. Subclone glti gene encoding GluBP 600n from pRSET FLIPE 600n (ECFP-ybeJ-Venus) into pET30b 513 
(His-fusion expression vector) at BglII and NotI restriction sites.  514 
Expression and purification of new GEGIs Timing 3 days (10 h hands-on time) 515 
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5. Transform 1 μL of iGluSnFR variants or GluBP 600n plasmid DNA into 50 μL of E. coli BL21 (DE3) 516 
gold chemically competent cells.  517 
6. Pick one colony and grow in 10 mL LB-medium supplemented with 100 µg/mL kanamycin for 518 
overnight at 37°C and 180 rpm (pre-culture). 519 
7. Inoculate 1 L LB-medium containing 100 µg/mL kanamycin with whole pre-culture, incubate at 520 
37°C and 180 rpm until OD600 reaches (0.6-0.8). 521 
8. Cool the cells down to 20°C. 522 
9. Induce protein expression with 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and 523 
incubate at 20°C and 180 rpm overnight.  524 
CRITICAL STEP: Best protein yields are obtained when inducing expression during exponential 525 
phase of growth (OD600 0.6-0.8), overnight at 18-20 °C. 526 
10. Harvest cells by centrifugation at 3000 g for 15 min at room temperature, resuspend cells in 527 
40 mL resuspension buffer supplemented with Pierce Protease Inhibitors and lyse via sonication 528 
on ice for 2 min (2 sec “on” and 8 sec “off”). 529 
CAUTION: Wear ear protection equipment during sonication. 530 
CRITICAL STEP: Sonication produces heat and may result in the degradation of your protein of 531 
interest. Performing sonication on ice and in the presence of protease inhibitors will dramatically 532 
limit this phenomenon. 533 
11. Remove the cell debris by ultracentrifugation at 100,000 g for 45 min at 4°C. 534 
CRITICAL STEP:  After cell lysis, all steps are performed at 4°C when possible to avoid protein 535 
digestion by cellular proteases (steps 12-14). 536 
12. Load the supernatant on equilibrated HisTrap HP column (nickel affinity resin) mounted on an 537 
ÄKTA system (flow rate 4 mL/min) and wash with 40 mL resuspension buffer. 538 
13. Elute the protein with 10 column volumes of a linear gradient of resuspension and elution buffer 539 
(0 to 0.5 M imidazole) and collect in 2 mL fractions. Analyze the purified protein by SDS-PAGE 540 
and stain the gel with Coomassie blue. 541 
14. Pool fractions of interest and dialyze overnight at 4°C in a snakeskin dialysis tubing (3.5 kDa) 542 
against 4 L storage buffer. 543 
CRITICAL STEP: It is essential to perform dialysis to remove the imidazole from your buffer. 544 
Otherwise, protein precipitation will occur upon defrosting  (from step 15). The dialysis 545 
molecular weight cut-off used can be higher than 3.5 kDa as long as it is below 15 kDa. 546 
15. Store purified protein in fractions of 1 mL in the -80°C freezer. 547 
PAUSE POINT: The purified protein can be stored at -80°C for up to 3 years. 548 
Determining the dynamic range Timing 1 h 549 
16. Prepare 50-100 nM iGluSnFR proteins in assay buffer, add to a Hellma micro cuvette (50 μL) and 550 
place the cuvette into a fluorescence spectrometer pre-equilibrated to 20 °C. 551 
17. Record the fluorescence emission spectrum (λex = 492 nm and λem = 497-550 nm) (F-glu). 552 
18. Add 10 mM glutamate solution to the micro cuvette, mix well and record the fluorescence 553 
emission spectrum (λex = 492 nm and λem = 497-550 nm) (F+glu). 554 
19. To analyze the data, take the maximal emission (around 514 nm) of each measurement and 555 
calculate the fluorescence dynamic range ((F+glu- F-glu)/F-glu).  556 
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20. Repeat Steps 16-19 twice in order to generate 3 independent replicates. 557 
CRITICAL STEP: If the fluorescence dynamic range is < 2 the fluorescence change upon glutamate 558 
binding is too low for imaging in hippocampal slices. In that case, try using higher concentrations 559 
of glutamate. If the fluorescence dynamic range has not improved, return to the "Selection of 560 
residues close to binding pocket step" and select another mutation. 561 
Determining Kd and specificity Timing 2 h for each ligand 562 
21. Prepare 50-100 nM GEGI in 3 mL assay buffer in a 3500 µL Hellma Quartz cuvette (QS). 563 
22. Add a magnetic stir bar and place the cuvette into spectrofluorometer. 564 
CRITICAL STEP: Make sure stir bar is moving rigorously. 565 
23. Fill a 250 µL Hamilton syringe with assay buffer with appropriate ligand: L-glutamate (10x Kd 10-566 
50 mM), L-aspartate (10x Kd 10-50 mM) or L-serine (10x Kd 10-50 mM).  567 
CRITICAL STEP: Make sure there are no air bubbles in the syringe nor in the tubing. 568 
24. Install the syringe in an Aladdin syringe pump, set the flow rate to 10 µL/min and place the 569 
tubing outlet carefully into the micro cuvette. 570 
25. Simultaneously start the recording of the fluorescence emission over time (λex = 492 nm and 571 
λem = 514 nm) and the syringe pump. 572 
26. To analyze the data, use time information to calculate the ligand concentration in the cuvette at 573 
each given time point. Correct the fluorescence emission for dilution/photobleaching and 574 
normalize it. Plot the corrected and normalized fluorescence against the ligand concentration 575 
and fit with a Hill equation for specific binding (GraphPad Prism 7) to obtain affinity for 576 
glutamate (Kd) and cooperativity of binding (n).  577 
27. Repeat Steps 21-26 twice in order to generate at least 3 independent experiments. 578 
Measuring kinetics Timing 5 h (4h for association, 1h for dissociation) 579 
CRITICAL: Temperature control is essential for all kinetic measurements. Furthermore, washing the 580 
instrument firmly after changing the ligand concentration is critical. To correctly analyze the data 581 
baselines and maximum fluorescence intensity lines should be recorded as described below. Always 582 
average at least five records (“shots”) for each measurement to obtain a representative trace. 583 
28. Association (Steps 28-32): Mix 1 µM GEGI in assay buffer with the maximal glutamate 584 
concentration in assay buffer (10x Kd, as determined in Step 27). Set the fluorescence level after 585 
mixing to reach 80% detector saturation by adjusting the gain on the PMT (reference of 1 for 586 
normalization). This step will prevent detector overload in future experiments. 587 
29. Mix assay buffer with assay buffer and record the baseline (reference of 0 for normalization).  588 
30. Mix 1 µM GEGI in assay buffer with assay buffer. This measurement should result in a straight 589 
line and shows the basal fluorescence without ligand bound. 590 
CRITICAL STEP: Steps 28-30 need to be performed before starting any association kinetic 591 
measurement of a GEGI. It ensures that the instrument is calibrated for maximum/minimum 592 
fluorescence detection levels and prevents detector damage. 593 
31. Glutamate dependent association kinetics: Mix 1 µM iGluSnFR variant in assay buffer with 594 
increasing glutamate concentrations in assay buffer (0.1x to 10x Kd). Record and average five 595 
measurements for each glutamate concentration. 596 
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CRITICAL STEP: You may have to perform measurements of different time scales to have enough 597 
data points for an accurate exponential fitting. Make sure you use about 10 different glutamate 598 
concentrations to measure the fluorescence increase with increasing glutamate and also the 599 
saturation as shown by reaching a maximum in fluorescence and on-rate.  600 
32. To analyze the data, normalize the recorded time traces to the PMT baseline and the maximal 601 
fluorescence level. Fit the time traces with mono- or biexponential decays (Kinetic studio or 602 
GraphPad Prism 7). Plot the obtained observed rate constants against the glutamate 603 
concentration. 604 
 605 
33. Dissociation (Steps 33-37): Mix 1 µM GEGI in glutamate saturating assay buffer (10x Kd, as 606 
determined in Step 27) with the same buffer. Set the fluorescence level after mixing to reach 607 
80% detector saturation by adjusting the gain on the PMT (reference of 1 for normalization). This 608 
step will prevent detector overload in future experiments. 609 
34. Perform step 29 to obtain the reference for 0. 610 
35. Perform step 30 to obtain the basal fluorescence level. 611 
CRITICAL STEP: Steps 34-35 need to be performed before starting any dissociation kinetic 612 
measurement of a GEGI. It ensures that the instrument is calibrated for maximum/minimum 613 
fluorescence detection levels and prevents detector damage. 614 
36. Dissociation kinetics: Mix 1 µM GEGI in assay buffer with saturating glutamate concentration 615 
(10x Kd) with 2 mM GluBP 600n in assay buffer. Higher concentrations of GluBP 600n are not 616 
advisable as precipitation might occur. Record and average five measurements. 617 
CRITICAL STEP: You may have to perform measurements of different time scale to have enough 618 
data points for an accurate exponential fitting. 619 
37. To analyze the data, normalize the recorded time traces to the PMT baseline and the maximum 620 
fluorescence level. Then fit the time trace with mono- or biexponential decays (Kinetic studio or 621 
GraphPad Prism 7). Plot the obtained observed rate constants against the glutamate 622 
concentration. 623 
Determining fluorescence dynamic range and Kd in HEK293T cells Timing 2 days (5 h hands-on 624 
time) 625 
38. Seed ~200,000 cells onto 24-well glass bottom fluorescence plates in complete DMEM and let 626 
them attach for 24 h in the incubator (37°C, 5% (v/v) CO2). 627 
39. Transfect the cells with GEGI plasmids generated by SDM of promising mutations into the 628 
mammalian expression vector pCMV iGluSnFR using Lipofectamine 2000 following the 629 
manufacturer's protocol.  630 
40. Examine the cells 24 h post-transfection at 37 °C with a confocal microscope (light source 631 
488 nm, using GFP settings). Check for localization at the plasma membrane. 632 
41. Glutamate titration: add stepwise glutamate to final concentrations between 0-10x Kd (as 633 
determined in Step 27) and take an image of the cells before and after each addition step. 634 
CRITICAL STEP: Focus drift may happen when you add glutamate. If it is the case, discard the last 635 
data-point and move to a different well. 636 
42. Define elliptical regions of interest (ROI) along cell membrane and determine the fluorescence 637 
intensity (ImageJ). Normalize intensity for each individual cell and average over a total number 638 
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of >20 cells. Plot relative intensity versus glutamate concentration and fit data with Hill equation 639 
(GraphPad Prism 7).  640 
Cloning in neuronal expression vector Timing 7 days (5h hands-on time) 641 
43. Use QuikChange XL site-directed mutagenesis kit to insert mutation of promising GEGI variants 642 
into pCI syn iGluSnFR vector and confirm by DNA sequencing. 643 
44. Prepare plasmid for electroporation using a plasmid DNA preparation kit (e.g. PureLink HiPure 644 
Maxiprep kit from Life Technologies) 645 
Culture preparation Timing 15 min/brain  646 
45. Prepare organotypic slice cultures (rat hippocampus)as described in 30. 647 
Single-cell electroporation Timing 10 min plus 10-20 min per slice, depending on slice quality and 648 
number of cells to transfect 649 
46. Preparation of plasmids and DNA (Steps 46-47): Sterile filter an aliquot (0.5 ml) of K-gluconate-650 
based intracellular solution through a Millipore Ultrafree centrifugal unit by centrifugation at 651 
16,000 g for several seconds in a table-top centrifuge at 4°C. 652 
47. Add the GEGI plasmids to the desired concentration after removal of the filter insert. Use 40 to 653 
50 ng/µL for pCI syn iGluf (Addgene plasmid #106121) or pCI syn iGluu (Addgene plasmid 654 
#106122) 13. For different cell types and GEGIs, the final concentration may have to be 655 
determined empirically (range: 1-100 ng/µL).  656 
CRITICAL STEP: It is important that the DNA-containing solution is not passed through the 657 
Millipore Ultrafree centrifugal filter unit. 658 
CRITICAL STEP: To aid visualization of axons and boutons of transfected neurons, mix plasmid 659 
encoding for red fluorescent protein (e.g. tdimer2; 20 ng/µL) with GEGI plasmid to achieve co-660 
expression.  661 
 662 
PAUSE POINT: The electroporation solution containing the plasmid can be stored between 663 
electroporation sessions at -20°C for up to 1 year. 664 
  665 
48. Electroporation (Steps 48-56): Coat silver wires tips and ground electrodes with AgCl by bathing 666 
them in a saturated Cl3Fe solution for at least 30 min or overnight prior to first use. 667 
49. Pull electroporation pipettes using a micropipette puller (e.g. PC-10, Narishige). Pull thin-walled 668 
borosilicate capillaries to obtain a resistance of 10-15 MΩ when filled with the intracellular 669 
solution.  670 
CRITICAL STEP: Ensure constant pipette resistance for reproducible expression. A too high 671 
pipette resistance leads to low expression, whereas a too low resistance causes extreme 672 
expression levels and toxicity. 673 
50. Back-fill an electroporation pipette with ~1.2 µL of plasmid mix solution (from Step 47) for each 674 
slice to electroporate. Back-filled pipettes can be kept (in an upright position) for up to 2 hours 675 
before use. Pipette 1 mL of transduction solution (37˚C) into the microscope chamber. Transfer 676 
one slice culture insert into the chamber (sterile forceps) and add transduction solution on top of 677 
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the slice culture for the water immersion objective. Use a sterile 60-mm dish to cover the 678 
microscope chamber to transfer to the microscope to proceed to single cell electroporation.  679 
CRITICAL STEP: To avoid any contamination place forceps into the hot bead sterilizer for ~ 10 sec 680 
before any handling of insert. 681 
CRITICAL STEP: Work on an electrophysiology microscope setup in a laminar flow box (see 682 
Equipment section) to prevent contamination. 683 
51. Apply positive pressure to the pipette to approach a cell to electroporate. Monitor by audio 684 
output of the Axoporator 800A amplifier the tip resistance of the electroporation pipette 685 
throughout the entire procedure. The resistance should be between 10–15 MΩ. 686 
CRITICAL STEP: Similarly to patch-clamp recording technique, positive pressure on the 687 
electroporation pipette is maintained to keep the tip of the pipette clean while penetrating the 688 
tissue. 689 
CRITICAL STEP: For reproducible expression level of the plasmids between different 690 
electroporation sessions, ensure that the pipette resistance is constant.  691 
52. Move the tip of the electroporation electrode close to a cell of interest while reducing the 692 
positive pressure.  693 
53. Approach the cell without sealing the electrode with membranes from other cells in the tissue. 694 
Touch the plasma membrane which causes a rise in tip resistance indicated by a rise in pitch. 695 
Immediately release the pressure and wait for the resistance to increase to 25–40 MΩ. Do not 696 
apply suction and avoid the formation of a GΩ seal.  697 
54. Apply a pulse train (e.g., voltage: −12 V, frequency: 50 Hz, pulse width: 500 µs, train duration: 698 
500 ms). The optimal settings may differ depending on the cell type to electroporate. 699 
CRITICAL STEP: For more reproducible expression levels of the plasmids between different cells, 700 
try to wait for the resistance to increase to a similar value before applying the pulse train. 701 
55. Slowly retract the pipette and begin applying very light positive pressure once the pipette is 702 
retracted 2–4 µm away from the soma. Increase the positive pressure at more considerable 703 
distances from the electroporated cell in order to maintain the pipette tip clean. Using the same 704 
electrode, repeat steps 51-55 for each cell to be electroporated. 705 
56.  Cover the chamber with a 60-mm dish and transfer back to the tissue culture hood. Remove all 706 
transfection medium and return the insert to the slice culture medium. Typically, 2-4 days are 707 
needed for optimal expression levels of GEGIs in hippocampal organotypic slices. However, the 708 
optimal time for a cell to express a given plasmid before starting the experiment has to be 709 
determined empirically 37. 710 
Stimulating transfected neurons Timing 30-90 min per recording depending on slice quality, 711 
the number of cells expressing the electroporated plasmids and the length of the recording 712 
57. Start temperature-controlled perfusion system and place the organotypic culture in the 713 
recording chamber. Weigh down membrane patch with c-shaped gold wire. 714 
? TROUBLESHOOTING 715 
58. Tune the Ti:Sapph laser to 980 nm for simultaneous excitation of tdimer2 and GEGI. 716 
? TROUBLESHOOTING 717 
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59. Approach a transfected CA3 neuron with the patch pipette, switching between red 718 
epifluorescence and IR-Dodt contrast (CCD camera). 719 
? TROUBLESHOOTING 720 
60. Establish a GΩ-seal and break in to establish whole-cell configuration. 721 
CRITICAL STEP: Stimulate an individual transfected cell to avoid stimulation of presynaptic 722 
terminals close to the terminal under scrutiny. This will ensure that the GEGI transients originate 723 
from the imaged terminal and are not a consequence of glutamate spillover. 724 
61. Move the stage to center the objective on CA1. Search for red fluorescent axons using two-725 
photon excitation. 726 
? TROUBLESHOOTING 727 
Imaging synaptic glutamate release  728 
62. Scan modality and signal analysis depend on the synaptic parameter under scrutiny. To localize 729 
the fusion site, acquire fast frame scans followed by fitting with a Gaussian kernel (Option A). To 730 
analyze the amplitude of glutamate transients, acquire spiral scans (Option B). To extract the 731 
amplitude, define a region of interest in every trial and fit an exponential decay function to the 732 
extracted time course.   733 
 734 
(A) Fusion site localization Timing 1 hour per recording 735 
i. Inject current pulses (2-3 ms, 1.5-3.5 nA) into the soma and acquire rapid frame scans of a single 736 
bouton (high zoom, 16 x 16 pixels, 1 ms/line). 737 
ii. Treat the raw images by a wavelet method to reduce photon shot noise 38 and improve SNR. 738 
? TROUBLESHOOTING 739 
iii. Upsample the images to 128 x 128 pixels (Lanczos kernel). 740 
iv. Align the images using a Fast Fourier transform (FFT) performed on the red fluorescence signal 741 
(tdimer2). 742 
v. Define a morphology mask to define a continuous area encompassing bouton and axon (pixel 743 
intensity ≥ 10% to 30% maximal intensity). 744 
vi. Calculate the relative change in GEGI fluorescence (∆F/F0) pixel by pixel using the mean of 5 745 
baseline frames as F0. Calculate the relative change and average the top 3% pixel values (of the 746 
GEGI signal) within the bouton mask to obtain the peak amplitude. 747 
vii. Construct a template (2-D anisotropic Gaussian kernel) from the average of 5 trials classified as 748 
success. A trial is classified as success when the peak amplitude is above 2σ of the baseline 749 
frames. 750 
viii. Perform a first round of analysis where fitting the template to every single frame by adapting 751 
only the amplitude and keeping the location and shape of the kernel fixed at the template values 752 
to obtain a preliminary classification of ‘successes’ (∆F/F0 > 2σ of baseline noise) and ‘failures’ 753 
(∆F/F0 < 2σ of baseline noise). 754 
ix. Repeat the fitting procedure on all trials classified as successes (step viii) allowing for variable 755 
location in order to localize the fusion site 756 
? TROUBLESHOOTING 757 




? TROUBLESHOOTING 760 
 (B) Amplitude extraction and failure analysis Timing 1 hour per recording 761 
i. Inject current pulses (2-3 ms, 1.5-3.5 nA) into soma and acquire rapid frame scans of a single 762 
bouton (high zoom, 16 x 16 pixels, 1 ms/line). 763 
ii. If a bouton shows AP-induced fluorescence increase (green channel), switch to spiral scan mode. 764 
? TROUBLESHOOTING 765 
iii. Acquire AP-induced GEGI transients at regular intervals (10 s), using 500 or 1000 Hz sampling. 766 
Image only for the duration of the GEGI transients (~20 to 80 ms) to minimize laser exposition. 767 
iv. For amplitude extraction, linearize the spiral scans and display them as xt-plots (Fig. 5c). 768 
v. To distinguish successful glutamate release events from failures, perform a statistical comparison 769 
of fluorescence fluctuations before stimulation (ΔF baseline, n = 64 columns/locations) and 770 
response amplitude (ΔF response, n = 64 columns/locations). A significant difference suggests a 771 
success, lack of significance a failure trial. This classification is preliminary; the final failure 772 
analysis is performed after amplitude extraction (step xi). 773 
vi. As there may be lateral drift between individual trials, it is necessary to assign a new region of 774 
interest (ROI) for each success trial. The spiral scan covering the entire bouton may hit the GEGI 775 
transient once or several times per line. Sort the pixel columns (i.e., spatial positions) according 776 
to the change in fluorescence (ΔF) in each column (Fig. 5d). In a given trial, only the columns 777 
which display a clear change in fluorescence (ΔF > ½ max ΔF) are analyzed (ROI). The threshold is 778 
once adjusted according to the noise of the imaging system but should be kept constant for 779 
amplitude comparisons between different experiments. 780 
vii. In failure trials, evaluate identical columns/locations than in the last success trial. 781 
viii. If necessary, correct traces for GEGI bleaching (see Box 1). 782 
ix. For each bouton, extract the characteristic decay time constant (τ) by fitting a mono-exponential 783 
function to the average GEGI fluorescence transient.  784 
x. Estimate the glutamate transient amplitude for every trial by fitting an exponential function to 785 
the decay of the fluorescence transient (fixed τ, amplitude as the only free parameter). 786 
? TROUBLESHOOTING 787 
xi. For each trial, determine the imaging noise (σ) from the baseline of the extracted fluorescence 788 
time course. Classify as ‘success’ trials where average ΔF/F0 > 2σ above baseline imaging noise, 789 
otherwise classify as ‘failure’. 790 
Box 1: Bleaching of GEGI 791 
During imaging, some GEGI molecules bleach, leading to a decrease in baseline fluorescence during each 792 
trial (Supplementary Figure 1). This may cause problems when fitting an exponential function to the 793 
decay of the glutamate response, since at least two time constants have to be taken into account. To 794 
correct individual trials from one bouton for bleaching, fit an exponential decay function to the average 795 
of several ‘failure’ trials. Subtract this function from each trial (failures and successes; step 63B viii). 796 
Between trials, fluorescence partially recovers, indicating lateral diffusion of GEGI molecules in the 797 
axonal membrane. Some loss of GEGI fluorescence (20-40%) during the course of the experiment can be 798 
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tolerated since it does not affect the glutamate-induced relative change in fluorescence (ΔF/F0, 799 
Supplementary Figure 1). We found that manual refocusing between trials can lead to substantial 800 
bleaching of the indicator. This can be minimized by automated refocusing between trials. 801 
Troubleshooting  802 
Step 57: Slices are contaminated. See 30 for proper slice culture handling. 803 
Step 58: No cells express the construct. Ensure that the constructs are incorporated into the target cells 804 
by adding a fluorescent dye such as Alexa Fluor 594 to the DNA mix (Step 47). After applying the pulse 805 
train to the target neuron (Step 54), take a fluorescence image (e.g., Leica Z6 APO) to ensure that the 806 
DNA solution and fluorescent dye were successfully electroporated. For more details for the 807 
electroporation procedure refer to 37. 808 
Step 59: Cells are dying after transfection with the constructs. Lower the expression of the GEGI, ensure 809 
that the pipette resistance (Step 49) is not lower than 10-15 MΩ in the bath before electroporation, 810 
and/or reduce expression time. A large pipette tip diameter (low resistance) can lead to overexpression 811 
of the GEGI and cell toxicity. Cells should be imaged 2-4 days after electroporation, as longer expression 812 
of GEGIs can affect cell health.  813 
CAUTION: Very strong promoters (CMV) should not be used for physiological experiments in neurons.  814 
Step 61: Slice is drifting, focus is not stable. Lower the perfusion rate. Check that the temperatures of the 815 
perfusion solution and of the imaging chamber of the microscope are stable to avoid thermal expansion 816 
during the experiment. 817 
Step 62A (ii): The responses are very weak and barely above noise. Wait longer after electroporation for 818 
a higher expression level. If the expression levels are too low, the GEGI signal from a single vesicle may 819 
be below the detection limit. The detection limit is determined by the noise level of the optical recording 820 
setup. Minimize background fluorescence, which can be caused by leaking room light, stray pump laser 821 
photons (green), or excessive dark counts in aging PMTs. Condenser detection is sensitive to the 822 
refractive index of the immersion oil and correct (Köhler) position. 823 
Step 62A (ix): The localization seems inaccurate. Calibrate the optical and mechanical performance of 824 
your system using fluorescent microbeads. Imaging of microbeads (0.17 µm diameter) positioned next to 825 
a fluorescent presynaptic terminal allows quantifying the accuracy of the response localization 826 
procedure.  827 
Step 62A (x): In cases where the positions of apparent ‘failures’ clusters in a second area of the bouton, 828 
exclude the bouton from further analysis as it might be a multi-synapse bouton. 829 
 830 
Step 62B (ii): The success rate in finding a bouton releasing glutamate is very low. This can be due to low 831 
release probability. Check [Ca2+] of the ACSF. 832 
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Step 62B (x): In some trials, the baseline fluorescence may show large fluctuations caused by green 833 
fluorescent vesicles passing through the axon. Remove these trials from further analysis. 834 
Timing 835 
 Steps 1-4 Generation of GEGIs    7 days (5 h hands-on-time) 836 
 Steps 5-15 Expression and purification of new GEGIs 3 days (10 h hands-on-time) 837 
 Steps 16-20 Dynamic range determination   1 h 838 
 Steps 21-27 Kd determination    2h/ligand 839 
 Steps 28-32 Association kinetics    4 h/variant 840 
 Steps 33-37 Dissociation kinetics    1 h/variant 841 
 Steps 38-42 Determination of dynamic range and Kd in cells 2 days (5 h hands-on time) 842 
 Steps 43-44 Subcloning into neuronal expression vector 7 days (5 h hands-on time) 843 
 Step 45  Culture preparation    15 min/brain 844 
 Steps 46-47 Preparation of plasmids and DNA  10 min 845 
 Steps 48-56 Single-cell electroporation   10-20 min/slice 846 
 Steps 57-61 Stimulating transfected neurons  30-90 min/recording 847 
 Steps 62A (i-x) Fusion site localization    1 h/recording 848 
Steps 62B (i-xi) Amplitude extraction and failure analysis 1h/recording 849 
Anticipated results 850 
Assessing the properties of neighboring boutons  851 
Once a responding bouton is identified, several neighboring boutons along the same axon can be imaged 852 
sequentially. Neighboring boutons frequently have similar release probabilities and response amplitudes 853 
(Fig. 6a). In rare cases, however, we found dramatic differences in response amplitude between 854 
neighboring boutons (Fig. 6b). To test whether boutons on the same axon are functionally similar, we 855 
generated random pairs by drawing from our entire set of characterized boutons. The differences 856 
between randomly selected boutons are normally distributed (black bars in Fig. 6d). The actual 857 
difference between neighboring boutons (red line in Fig. 6d) is at the low end of the distribution, 858 
indicating that neighboring boutons tended to have similar release probabilities. A similar result, 859 
however non-significant, was found when response amplitudes were analyzed (Fig. 6e and f).   860 
Application of fast GEGIs 861 
While iGluSnFR has an excellent SNR, it is too slow to resolve vesicle fusion events during high-frequency 862 
transmission 39. Recently developed ultrafast GEGIs, iGluu and iGluf 13 resolve individual responses during 863 
100 Hz trains, albeit with slightly lower SNR as shorter transients correspond to fewer photons collected 864 
(Fig. 7a). For these experiments, scan speed was increased to 1 kHz, and a high Ca2+ solution was used to 865 
increase release probability. Under these conditions, individual boutons typically had a release 866 
probability of 1 on the first AP, which rapidly dropped to ~0.2 towards the end of the 100 Hz train. After 867 
a brief recovery period (0.5 s), most boutons could restore their initial high release probability (Fig. 7b 868 
and c). Interestingly, the depression also affected the amplitude of individual successes, suggesting a 869 
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switch from multivesicular release (MVR) to univesicular release during high-frequency activity 1,40. 870 
Alternatively, a switch from full fusion to partial fusion of synaptic vesicles41 could explain this 871 
observation. Responses from an iGluSnFR-expressing bouton during high-frequency stimulation are 872 
shown for comparison (blue traces, Fig. 7a). Summation of 100 Hz release events drives this slow GEGI 873 
towards saturation, making it impossible to disentangle single-pulse responses by deconvolution. As 874 
saline with high calcium concentration (4 mM) was used in these experiments, the prevalence of MVR 875 
under more physiological conditions remains to be investigated. In this context, an important advantage 876 
of GEGI measurements compared to GECIs42 is their independence from extracellular [Ca2+], allowing to 877 
investigate the impact of changes in [Ca2+]e on presynaptic function43. In summary, ultrafast GEGIs allow 878 
direct visualization of short-term plasticity at individual synapses and may help unraveling the underlying 879 
biophysical mechanisms. 880 
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 Figure legends 989 
Fig 1: Overview of the protocol workflow for the development of glutamate sensors and 2-990 
photon imaging of glutamate transients in individual synapses. 991 
Fig 2: Characterization of GEGIs. 992 
(a) Left: Setup for affinity and selectivity determination. GEGI in assay buffer is placed into a fluorescence 993 
cuvette with a magnetic stirrer and placed inside the sample chamber of the fluorescence spectrometer 994 
(Fluorolog3, Horiba Scientific). With an Aladdin pump, the ligand (Glu, Asp, Ser) is continuously added to 995 
the cuvette while the fluorescence is recorded (λex = 492 nm,  λex = 514 nm). Right: Examples of affinity 996 
curves of a GEGI for glutamate (black squares) and aspartate (black circles). The fluorescence emission is 997 
corrected for dilution and bleaching and plotted against the glutamate concentration in the chamber. 998 
The data is then fitted with a Hill equation (green and orange traces for glutamate and aspartate, 999 
respectively). (b) Left: Setup for stopped-flow kinetic measurement. The solutions are rapidly mixed in 1000 
the mixing chamber and then pushed into the optical cell where the fluorescence is excited at 492 nm 1001 
and emission is detected by a PMT with a cut-off filter (>530 nm). For association the GEGI in assay 1002 
buffer without glutamate is loaded into the drive syringe B and mixed with assay buffer containing 1003 
increasing concentrations of glutamate filled in drive syringe A. For dissociation the GEGI in assay buffer 1004 
with saturating glutamate concentration is loaded into the drive syringe B and mixed with GluBP 600n in 1005 
assay buffer filled into drive syringe A. For both measurements the PMT zero level is determined by 1006 
mixing assay buffer with assay buffer and the intrinsic fluorescence of the GEGI is recorded by mixing the 1007 
GEGI in assay buffer with assay buffer (both without Glu). Right: Examples for recorded time traces. Top: 1008 
Fluorescence increase observed when GEGIs are mixed with increasing glutamate concentration. 1009 
Bottom: Decrease in fluorescence when glutamate is retained from GEGI by GluBP 600n. The raw data 1010 
are fitted with monoexponential decays (dark green line).  1011 
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Fig 3: iGluSnFR expression in CA3 pyramidal cells in organotypic slice culture of rat 1012 
hippocampus. 1013 
(a) Co-expression of two plasmids in individual CA3 pyramidal cells in organotypic slice culture. The red 1014 
fluorescent protein tdimer2 labels the axoplasm while the membrane-anchored iGluSnFR is exposed to 1015 
the extracellular space. (b) Transmitted light image (dark field) of a transfected organotypic culture 1016 
merged with a wide-field fluorescence image showing three transfected CA3 neurons. The area for 1017 
synaptic imaging is indicated (red dotted box). Scale bar represents 500 µm.  (c) Two-photon image stack 1018 
(maximum intensity projection) of CA3 axons in CA1 stratum radiatum (cells not identical to panel b).  1019 
Scale bar represents 10 µm. Image from 13. (d) Maximum intensity projection of two-photon images of 1020 
CA3 pyramidal neuron expressing iGluu 4 days after electroporation (fluorescence intensity is shown as 1021 
inverted gray values). iGluu shown here and other GEGIs had their fluorescence mainly localized to the 1022 
plasma membrane over the entire cell. The scale bar represents 50 µm (left image) and 5 µm (right 1023 
image). (e) Action potentials are elicited in a transfected neuron by somatic current injections and 1024 
glutamate release is simultaneously optically recorded (GEGI fluorescence) from a single Schaffer 1025 
collateral bouton in CA1, showing a broad distribution of amplitudes and occasional failures. Images 1026 
were acquired at 500 Hz at 34°C. Individual trials are classified as successes if the peak amplitude of the 1027 
GEGI transient is >2σ (green traces) and as failures when the peak amplitude is <2σ (gray traces). Note 1028 
propagation delay between presynaptic APs and glutamate release events at distal bouton. 1029 
Fig 4: Localization of fluorescence transients in low and high [Ca2+]o.  1030 
(a) Morphology of individual boutons. Red fluorescence was upsampled (16 x 16 pixels to 128 x 128 1031 
pixels), aligned and averaged over all trials. Scale bars represent 0.5 µm. (b) Average response of 1032 
iGluSnFR superimposed with bouton outline (black line) from red channel (morphology). The bouton 1033 
outline was generated by thresholding the red channel followed by smoothing. (c) Two-dimensional 1034 
Gaussian fit to average response. On average, the full width at half maximum (FWHM) was 763 ± 29 nm 1035 
(n = 12; 5 boutons shown here) (d) Plotting the center position of 2D Gaussian fits to individual trials. 1036 
Fusion appears to be localized to a small region on the bouton (active zone). Amplitude (ΔF/F0) of 1037 
individual trials is color-coded. Scale bars represent 0.5 µm.  (e) Increasing the extracellular Ca2+ 1038 
concentration increased the amplitude of individual responses, but did not lead to release events outside 1039 
the active zone. (f) Fitting responses classified as failures (< 2σ of baseline noise) did not reveal any 1040 
clustering, indicating that there was indeed no localized signal in these trials (true negatives). (g) Fitting 1041 
frames before stimulation (green baseline fluorescence) did also not result in clustering.  1042 
Fig. 5: Signal extraction of GEGI transients from a single Schaffer collateral bouton in CA1. 1043 
(a) The spatial extent of iGluSnFR fluorescence transients was 760 nm, on average (FWHM, short axis of 1044 
Gaussian fits). No deconvolution was applied. (b) Sampling the surface of the bouton by traditional raster 1045 
scanning requires extreme acceleration of the scan mirrors at the turning points, leading to large 1046 
positional errors. Spiral scans avoid sharp direction changes (no flyback) and can, therefore, sample the 1047 
entire bouton surface in 1 or 2 ms. Due to the elongated PSF (1.8 µm in the axial direction), upper and 1048 
lower surface of a bouton are sampled simultaneously. (c) Plotting the unfolded spiral scan lines vs. time 1049 
(single trial). Raw fluorescence intensity is coded in pseudocolors. At t = 58 ms, a glutamate release 1050 
event from an individual presynaptic terminal occurred and was sampled twice during every spiral scan. 1051 
(d) Only columns with ΔF > ½ max (ΔF) were analyzed (ROI, region of interest). Green trace: Extracted 1052 
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fluorescence transient (before bleach correction). (e) Upper panel: Average of 10 trials (single APs) to 1053 
analyze lateral spread of signal from t=0 to t=18 ms. Lower panel: Decay of fluorescence transient (5 scan 1054 
lines plotted = 18 ms). Note the lack of lateral spread of the signal due to slow diffusion of membrane-1055 
anchored GEGI. (f) iGluSnFR response amplitude (green markers) of a single bouton stimulated with 1056 
single APs every 10 s. Note that response amplitudes were constant over time. A time window before 1057 
stimulation was analyzed to estimate imaging noise (gray markers). The histogram of response 1058 
amplitudes shows separation between failures of glutamate release (overlap with the baseline 1059 
histogram) and successes. 1060 
Fig. 6: Release statistics of neighboring boutons on the same axon.  1061 
(a) Glutamate transients (green dots) and baseline fluorescence (grey dots) of two neighboring boutons 1062 
measured in ACSF containing 2 mM Ca2+ and 1 mM Mg2+ located on the same axon (left panels) and their 1063 
corresponding histogram counts (right panels). (b) Glutamate transients (blue dots) and baseline 1064 
fluorescence (grey dots) of two neighboring boutons located on the same axon (left panels) and their 1065 
corresponding histograms (right panels) measured in ACSF containing 2 mM Ca2+ and 1 mM Mg2+ and 1066 
their corresponding histogram counts (right panels). (c) Synaptic release probability (pr) (calculated out 1067 
of ~ 100 trials) of individual boutons (B1) and their neighboring bouton on the same axon (B2); n=10. The 1068 
pair of neighboring boutons from (a) and (b) are shown in green and blue, respectively. (d) Histogram of 1069 
∆ pr = |pr BX-pr BY|. BX and BY are randomly paired from the dataset in (c). |∆pr B2- ∆pr B1| (red vertical 1070 
line) is significantly more similar than mean ∆ pr of two boutons paired randomly from the same dataset; 1071 
(p-value: 0.0148). (e) Amplitude of the iGluSnFR signal given a success of a bouton B1 and its neighbor on 1072 
the same axon (B2); n=10. The pair of neighboring boutons from (a) and (b) are shown in green and blue, 1073 
respectively. (f) Histogram count of the difference between the average ΔF/F0 of successes only of two 1074 
random neighboring boutons. The difference of the average ΔF/F0 of successes from two neighboring 1075 
boutons (red vertical line) is not significantly more similar than the randomly connected pairs of boutons. 1076 
Fig. 7: Resolving high-frequency transmission with ultrafast GEGI, iGluu. 1077 
(a) The presynaptic neuron was driven to spike at 100 Hz (10 APs). After a pause of 0.5 s, one more AP 1078 
was triggered to quantify recovery from depression. iGluSnFR signals (blue) or iGluu signals (green) were 1079 
recorded at single Schaffer collateral boutons (only during the 100 Hz train) in stratum radiatum. 1080 
Recordings were performed in 4 mM Ca2+ and 1 mM Mg2+ to ensure very high release probability. Note 1081 
summation and saturation of iGluSnFR (but not iGluu) during the high-frequency train. (b) iGluu responses 1082 
to the 1st AP of the 100 Hz train, to the 9th AP of the train, and to the recovery pulse. To minimize 1083 
bleaching, the bouton was only imaged (spiral scans) during pulses 1, 9 and 11. Note frequent failures in 1084 
response to pulse 9. (c) Extracted single-trial amplitudes reveal strong depression and full recovery of 1085 
this bouton. Failures of glutamate release can be seen in response to pulse 9. Note the large amplitude 1086 
of initial responses compared to depressed responses. Plots were generated with violinplot.m (GitHub, 1087 
©Bastian Bechtold). 1088 
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Culture preparation
Steps 46-47
Flowchart of sensor development
































































































































Sample chamber with 
cuvette and magnetic stirrer
492 nm
514 nm
a CN iGluSnFR 67%




















































































a dc e f g
av. ∆F/F
0





































































































2 4 6 8 10 120
e f


































































































































B 1 B 2







































































Bouton 1 Bouton 2


















































Pulse 1 Pulse 9 Pulse 11
